Cite
The PEGylated liposomal doxorubicin improves the delivery and therapeutic efficiency of 188Re-Liposome by modulating phagocytosis in C26 murine colon carcinoma tumor model.
MLA
Hsu, Wei-Hsin, et al. “The PEGylated Liposomal Doxorubicin Improves the Delivery and Therapeutic Efficiency of 188Re-Liposome by Modulating Phagocytosis in C26 Murine Colon Carcinoma Tumor Model.” Nuclear Medicine & Biology, vol. 41, no. 9, Oct. 2014, pp. 765–71. EBSCOhost, https://doi.org/10.1016/j.nucmedbio.2014.05.142.
APA
Hsu, W.-H., Liu, S.-Y., Chang, Y.-J., Chang, C.-H., Ting, G., & Lee, T.-W. (2014). The PEGylated liposomal doxorubicin improves the delivery and therapeutic efficiency of 188Re-Liposome by modulating phagocytosis in C26 murine colon carcinoma tumor model. Nuclear Medicine & Biology, 41(9), 765–771. https://doi.org/10.1016/j.nucmedbio.2014.05.142
Chicago
Hsu, Wei-Hsin, Si-Yen Liu, Ya-Jen Chang, Chih-Hsien Chang, Gann Ting, and Te-Wei Lee. 2014. “The PEGylated Liposomal Doxorubicin Improves the Delivery and Therapeutic Efficiency of 188Re-Liposome by Modulating Phagocytosis in C26 Murine Colon Carcinoma Tumor Model.” Nuclear Medicine & Biology 41 (9): 765–71. doi:10.1016/j.nucmedbio.2014.05.142.